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Abstract
Background: Binding of chemokines to glycosaminoglycans (GAGs) is classically described as initiating inflammatory cell
migration and creating tissue chemokine gradients that direct local leukocyte chemotaxis into damaged or transplanted tissues.
While chemokine-receptor binding has been extensively studied during allograft transplantation, effects of glycosaminoglycan
(GAG) interactions with chemokines on transplant longevity are less well known. Here we examine the impact of interrupting
chemokine-GAG interactions and chemokine-receptor interactions, both locally and systemically, on vascular disease in allografts.
Methodology/Principal Findings: Analysis of GAG or CC chemokine receptor 2 (CCR2) deficiency were coupled with the
infusion of viral chemokine modulating proteins (CMPs) in mouse aortic allograft transplants (n = 239 mice). Inflammatory
cell invasion and neointimal hyperplasia were significantly reduced in N-deacetylase-N-sulfotransferase-1 (Ndst1f/fTekCre+)
heparan sulfate (GAG)-deficient (Ndst12/2, p,0.044) and CCR2-deficient (Ccr22/2, p,0.04) donor transplants. Donor tissue
GAG or CCR2 deficiency markedly reduced inflammation and vasculopathy, whereas recipient deficiencies did not.
Treatment with three CMPs was also investigated; Poxviral M-T1 blocks CC chemokine receptor binding, M-T7 blocks C, CC,
and CXC GAG binding, and herpesviral M3 binds receptor and GAG binding for all classes. M-T7 reduced intimal hyperplasia
in wild type (WT) (Ccr2+/+, p#0.003 and Ccr22/2, p#0.027) aortic allografts, but not in Ndst12/2 aortic allografts (p = 0.933).
M-T1 and M3 inhibited WT (Ccr2+/+ and Ndst1+/+, p#0.006) allograft vasculopathy, but did not block vasculopathy in Ccr22/2
(p = 0.61). M-T7 treatment alone, even without immunosuppressive drugs, also significantly prolonged survival of renal
allograft transplants (p#0.001).
Conclusions/Significance: Interruption of chemokine-GAG interactions, even in the absence of chemokine-receptor
blockade, is a highly effective approach to reduction of allograft rejection, reducing vascular inflammation and prolonging
allograft survival. Although chemokines direct both local and systemic cell migration, interruption of inherent chemokine
responses in the donor tissue unexpectedly had a greater therapeutic impact on allograft vasculopathy.
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Introduction
Chemokines interact with both glycosaminoglycans (GAG) and
cell surface receptors. Both interactions accelerate and localize
inflammatory cell responses in damaged or transplanted tissues,
but how the interaction of chemokines with tissue polysaccharides,
particularly GAGs, regulate pathologic inflammatory responses is
only partially understood [1–4]. The relative impact of GAG
versus receptor interactions with chemokines on the progression of
transplant rejection is not known. Chemokines are small 8–12 kDa
proteins, organized into C, CC, CXC, and CX3C subclasses; the
CC class is traditionally defined as directing monocyte and
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lymphocyte activation and the CXC class as directing neutrophil
activation [1–3]. There is, however, extensive crossover of
receptor and cellular targets. Chemokines oligomerize on GAGs
to form three-dimensional concentration gradients that attract
cells to sites of tissue damage, such as in a fresh organ transplant.
These GAG-chemokine interactions are postulated to increase the
specificity of chemokine-directed chemotaxis of innate immune
cells when combined with receptor recognition [1–3]. Binding to
tissue and cell surface GAGs is thought to present the chemokine
N-terminus to inflammatory cell surfaces where the cognate seven-
transmembrane G-protein coupled chemokine receptors initiate
the signaling responses that drive leukocyte taxis. These interac-
tions directionally guide cells toward increasing concentrations of
chemokines and act as a primary defense to remove pathogens or
to begin repair responses after trauma, transplant, or injury [1–5].
Chemokines are also reported to direct trafficking of dendritic cells
[6] and lymphocytes [6–9] in bone marrow and secondary
lymphoid organs [lymph nodes, tonsil], as well as at local tissue
sites.
Transplant vasculopathy is a form of highly inflammatory
chronic transplant rejection that is one of the leading causes of
organ loss after the first year post transplant [10–12]. Up to 50%
of late transplant loss has been attributed to early damage and
innate immune or inflammatory, reactions (non acquired immune)
that are up-regulated in response to transplanted organ ischemia,
increased inflammatory cytokine expression in the donor and
surgical trauma.
Both acute and chronic rejection, as well as accelerated
transplant vasculopathy, are associated with increased chemokine
and chemokine receptor expression, including increased macro-
phage chemoattractant protein-1 (MCP-1, CCL2), macrophage
inflammatory protein-1a (MIP1a, CCL3), regulated on activation
T cell expressed and secreted (RANTES, CCL5), CCR2, and
CXCR3 among others [13–18]. Inflammatory cell recruitment,
vascular diseases, and rejection are reduced in mice with selected
deficiencies for certain chemokines or their receptors or after
treatment with inhibitory reagents that target chemokines such as
MCP-1 (CCL2)[19], CCR1 [20], CCR2 [19], CCR5 [21],
CX3CR1 [22], and CXCR3 [22]. The effects of inhibition or
down-regulation of individual chemokines in transplant rejection
can vary. For example, while atherosclerosis and rejection of
pancreatic islet cell transplants are consistently reduced in CCR2
deficient mice, transplant rejection was only minimally altered
after heart transplant into Ccr22/2 recipients [19–23].
The distribution of GAGs in the arterial wall also correlates with
vascular disease [3]. Heparan sulfate (HS), chondroitin sulfate,
dermatan sulfate, keratan sulfate, and hyaluronic acid are present
in the arterial wall on cells and interstitial connective tissue areas,
typically as proteoglycans [3,24]. Increased circulating GAGs are
detected in patients with acute renal transplant rejection, which
may reflect local degradation of proteoglycans [25]. The
importance of chemokine-Heparan sulfate interactions was
recently demonstrated in mice bearing a tissue-specific mutation
in the biosynthetic enzyme N-deacetylase/N-sulfotransferase-1
(Ndst1), which reduces the overall sulfation of HS chains [4].
Selectively inactivating the gene in endothelial cells and leukocytes
reduced inflammatory neutrophil cell invasion with deficiency for
chemokine-mediated transcytosis across cell layers. Based on bone
marrow transplantation, the phenotype was associated with Ndst1-
deficiency (Ndst12/2) in endothelial cells, whereas deficiency in
leukocytes had minimal effect [4]. Selectively inactivating the gene
in endothelial cells and leukocytes reduced inflammatory neu-
trophil cell invasion. Based on bone marrow transplantation
experiments, the phenotype was associated with Ndst1-deficiency
in endothelial cells, whereas deficiency in leukocytes had minimal
effect [4]. Chemokine binding to HS was also significantly reduced
in Ndst12/2 endothelial cells. Mutating the GAG binding epitopes
of chemokines also blocks cell migration in vivo in a mouse
peritoneal cell migration assay [26]. Conversely, HS has been
reported to prolong transplant function, reduce rejection [27] and
modify xenograft vasculopathy, suggesting an alternate anti-
inflammatory and protective role [28]. The role of GAGs and
specifically GAG-chemokine interactions in transplant vasculo-
pathy and rejection is not well understood.
Viral chemokine modulating proteins (CMPs) have highly active
anti-inflammatory functions that have evolved in large DNA
viruses over many millions of years. These CMPs can selectively
target both chemokine-GAG and chemokine-receptor interactions
[29–31]. M-T1 and M-T7 are secreted myxoma viral (rabbit)
CMPs; M-T1 interferes with receptor binding of CC chemokines,
and M-T7 interferes with GAG binding for C, CC, and CXC
chemokines [31–34]. M-T7 also binds interferon gamma (IFNc),
but only inhibits the rabbit ligand in a species-specific fashion [35–
37]. M3 is a secreted c68 herpesvirus protein that blocks both
receptor and GAG binding of C, CC, CXC, and CX3C
chemokines and reduces inflammatory cell invasion in mouse
herpes meningitis [38]. When infused as purified protein at the
time of aortic transplantation, M-T1, M-T7, and M3 significantly
reduced plaque growth in rat ACI to Lewis aortic allografts at 4
weeks [39]. Similarly, reduced vasculopathy and scarring were
observed in renal transplants at 5 months after 10 daily injections
of M-T7 together with cyclosporine, but without effects on overall
survival [40]. Reductions in inflammatory cell invasion and plaque
growth followed M-T7 treatment in both rat and rabbit
iliofemoral angioplasty balloon injury models, indicating that M-
T7 anti-inflammatory activity is not IFNc dependent but instead is
postulated to function through chemokine modulation, in a species
independent fashion [41].
In this study, we examine the effects of chemokine-GAG
interactions on inflammatory cell responses, vasculopathy devel-
opment, and graft survival in mouse aortic and renal transplant
models, with comparison to chemokine-receptor interactions. We
have detected significant local reductions in inflammatory cell
responses and vasculopathy development with either GAG or
CCR2 deficiency or after treatment with viral chemokine
modulating proteins (CMPs) targeting GAG or receptor binding.
Abdominal aortic transplants from donor mice deficient in HS-
GAG (Ndst12/2) or the chemokine CCR2 receptor (Ccr22/2)
displayed marked reductions in plaque growth while HS GAG or
CCR2 deficiency in the recipient mouse had minimal effects.
Similarly, mice treated with CMPs also had markedly reduced
inflammation and vasculopathy after aortic transplant. M-T7
treatment alone further reduced inflammatory cell invasion and
prolonged survival in mouse renal allograft transplants, even in the
absence of cyclosporine treatment.
Results
Deficiency of either Ndst1 or Ccr2 in aortic donor
segments reduces inflammation and vasculopathy after
aortic transplant in mouse models
The effects of either GAG or chemokine receptor deficiency on
vascular neointimal hyperplasia (plaque) growth, was examined in
mouse aortic allograft transplant models with donor aortic genetic
deficiency of Ndst1 or Ccr2 (Table 1, n = 79) and wild type
recipients. Excess inflammatory cell infiltration and neointimal
hyperplasia (accelerated plaque growth) were detected in aortic
allograft transplants at 4 weeks follow up in control, saline treated,
Chemokine-GAG in Transplant
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Table 1. Mouse aortic transplant model.
Donor Recipient Treatment Dose Total number Number 4 weeks
CCR2 deficiency Studies - Allografts mice (Survival%)
CCR2+/+ (Balb/C) WT (C57Bl/6) Saline 13 10
CCR2+/+ (Balb/C) WT (C57Bl/6) M-T1 0.6 ng 6 6
CCR2+/+ (Balb/C) WT (C57Bl/6) M-T1 0.6 mg 7 7
CCR2+/+ (Balb/C) WT (C57Bl/6) M-T7 0.6 ng 8 7
CCR2+/+ (Balb/C) WT (C57Bl/6) M-T7 0.6 mg 6 6
CCR2+/+ (Balb/C) WT (C57Bl/6) M-T7 6 mg 8 7
CCR2+/+ (Balb/C) WT (C57Bl/6) M3 0.6 ng 6 6
CCR2+/+ (Balb/C) WT (C57Bl/6) M3 0.6 mg 6 6
Subtotal 60 55 (92%)
CCR22/2 (Balb/C) WT (C57Bl/6) Saline 10 7
CCR22/2 (Balb/C) WT (C57Bl/6) M-T1 0.6 ng 6 6
CCR22/2 (Balb/C) WT (C57Bl/6) M-T1 0.6 mg 6 6
CCR22/2 (Balb/C) WT (C57Bl/6) M-T7 0.6 ng 8 7
CCR22/2 (Balb/C) WT (C57Bl/6) M-T7 0.6 mg 11 11
CCR22/2 (Balb/C) WT (C57Bl/6) M-T7 6 mg 12 11
CCR22/2 (Balb/C) WT (C57Bl/6) M3 0.6 ng 6 6
CCR22/2 (Balb/C) WT (C57Bl/6) M3 0.6 mg 6 6
Subtotal 65 60 (92%)
CCR2 deficiency - Reverse Allografts
CCR2+/+ (C57Bl/6) WT (Balb/c) Saline 6 6
CCR2+/+ (C57Bl/6) WT (Balb/c) M-T7 6 mg 7 6
Subtotal 13 12 (92%)
CCR2+/+ (C57Bl/6) CCR22/2 (Balb/C) Saline 7 6
CCR2+/+ (C57Bl/6) CCR22/2 (Balb/C) M-T7 6 mg 6 6
Subtotal 13 12 (92%)
CCR2 deficiency Studies - Isografts
CCR22/2 (Balb/C) CCR22/2 (Balb/C) Saline 7 6
CCR22/2 (Balb/C) CCR22/2 (Balb/C) M-T7 6 mg 7 6
Subtotal 14 12 (86%)
GAG deficiency Studies - Allografts
NDST1+/+ (C57Bl/6) WT (Balb/c) Saline 6 5
NDST1+/+ (C57Bl/6) WT (Balb/c) M-T7 6 mg 6 6
Subtotal 12 11 (92%)
NDST12/2 (C57Bl/6) WT (Balb/c) Saline 6 6
NDST12/2 (C57Bl/6) WT (Balb/c) M-T7 6 mg 6 5
NDST12/2 (C57Bl/6) WT (Balb/c) M-T1 15 mg 5 5
Subtotal 17 16 (94%)
GAG deficiency - Reverse Allografts
NDST-1+/+ (Balb/C) NDST-1+/+ (C57Bl/6) Saline 5 4
NDST-1+/+ (Balb/C) NDST-1+/+ (C57Bl/6) M-T7 6 mg 4 4
Subtotal 9 8 (89%)
NDST1+/+ (Balb/C) NDST12/2 (C57Bl/6) Saline 6 6
NDST1+/+ (Balb/C) NDST12/2 (C57Bl/6) M-T7 6 mg 6 6
Subtotal 12 12 (100%)
GAG deficiency - Isografts
NDST-12/2 (C57Bl/6) NDST-12/2 (C57Bl/6) Saline 6 6
NDST-12/2 (C57Bl/6) NDST-12/2 (C57Bl/6) M-T7 6 mg 5 5
Subtotal 11 11 (100%)
NDST-1+/+ (C57Bl/6) WT (C57Bl/6) Saline 7 6
Chemokine-GAG in Transplant
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wild type (WT) mice, using either C57Bl/6 donor to Balb/c
recipient mice (Fig. 1A,E) or Balb/c donor to C57Bl/6 recipient
mice (Fig. 1 C, E, n= 19). Transplantation of conditionally HS
deficient Ndst12/2 donor aorta (C57Bl/6 background) into WT
recipient (Balb/c background, Ndst1+/+) mice significantly reduced
plaque area (Fig. 1 B, E, n= 12), whether measured as the ratio of
intimal to medial thickness (72.9% reduction, P,0.044) or by
morphometric analysis of neointimal plaque area (72.4%,
P,0.05), when compared to WT donor aortic transplant (Balb/
c recipient) using littermate controls (Fig. 1 A, E). Similarly,
transplant of Ccr22/2 donor aorta (Balb/c background) into WT
(C57Bl/6 background, Ccr2+/+) recipient mice significantly
reduced neointimal hyperplasia (Fig. 1 D, E, n = 23) measured
as ratios of intimal to medial thickness (55.6%, P,0.040) or as
total neointimal cross-section area (43.5%, P,0.021) when
compared to WT (Ccr2+/+) littermate controls (C57Bl/6 recipient,
Fig. 1C, E). Although Ndst12/2 are on a C57Bl/6 background
and Ccr22/2 mice are on a Balb/c background, reductions in
intimal plaque area were detected in each analysis using
comparison to matched controls, e.g. WT C57Bl/6 to Balb/c
and WT Balb/c to C57Bl/6 (ANOVA p,0.027). A significant
difference in total intimal plaque area was detectable for saline
treated WT C57Bl/6 to Balb/c when compared to the C57Bl/6 to
Balb/c controls (n = 19, mean plaque area 0.1560.037 mm2 for
WT Balb/c versus 0.05260.013 mm2 for WT C57Bl/6 donor
allografts, P,0.034). However, no statistically significant increase
was seen on analysis of intimal to medial thickness (Fig. 1E, n= 19,
p = 0.521). Measurement of the intimal to medial thickness ratios
normalizes intimal plaque size to arterial medial thickness. All
analyses were performed using both intimal to medial thickness
ratios together with morphometric analysis of plaque area.
Isograft transplants were similarly examined to assess the effects of
Ndst1 or Ccr2 deficiency on isolated surgical injury. Isograft
transplants using WT mouse models displayed reduced plaque
areas at 4 weeks follow up, whether on a wild type C57Bl/6 or a
Balb/c background. Ndst12/2 and Ccr22/2 isograft transplants
demonstrated a further reduction in plaque size when compared to
allografts or WT isografts. The plaque area reduction was significant
when comparing Ndst1+/+ allografts with isografts, but, although
there is a trend toward a reduction in plaque size, there was no
significant change when comparing WT isografts to genetically
deficient isografts despite a trend toward a reduction in plaque size.
Mean plaque area was 0.03960.020 mm2 for Ndst1+/+ isografts,
and 0.01760.011 mm2 for Ndst12/2 isografts (n= 18; p= 0.891).
These studies indicate that deficiency of either Ndst1 or Ccr2 in
the transplanted donor aorta produced a marked reduction in
intimal plaque.
Local donor, but not systemic recipient Ndst1 or Ccr2
allograft deficiency, reduces inflammatory cell invasion
and plaque growth
Local interruption of chemokine-HS GAG and chemokine-
Ccr2 interactions was compared to systemic interruption, using
reverse transplantations with donor WT aortic segments im-
planted into Ndst12/2 or into Ccr22/2 mice. Reverse transplant of
Balb/c mouse aorta into Ndst12/2 (C57Bl/6 background)
recipient mice did not reduce plaque size or inflammatory cell
infiltrates when compared to Balb/c transplant into WT (Ndst1+/+)
recipient mice (Table 1, n= 11, p = 0.468, Fig. 1F). Transplant of a
WT C57Bl/6 background donor aorta into a Ccr22/2 (Balb/c
background) recipient mouse also did not significantly reduce
plaque size (Table 1, n = 13, p = 0.846, Fig. 1F) when compared to
transplant into WT (Ccr2+/+) recipients (ANOVA p=0.806).
Analysis of mean plaque area similarly demonstrated a trend
toward a reduction in plaque area, but no significant change when
comparing WT Balb/c donor aortic allograft transplant to C57Bl/
6 Ndst12/2 recipient or to WT C57Bl/6 recipient transplants
(28.9% reduction in intimal plaque area in the Ndst12/2
recipients, p = 0.484). No significant change was detected in WT
C57Bl/6 donor to Balb/c (Ccr2+/+) or to Ccr22/2 recipient
allograft transplants (Fig. 1F, 27.7% reduction in the intimal
plaque area, p = 0.709).
These studies indicate that local anti-inflammatory effects of
Ccr2 and Ndst1 deficiency inherent in the donor transplant, carried
over to the recipient mouse and have predominant effects on
plaque growth in the mouse aortic allograft transplant model.
Chemokine modulating protein (CMP) treatments
targeting chemokine-GAG or chemokine-CCR2
interactions reduce neointimal hyperplasia
To further examine the effects of selective blockade of
chemokine-GAG interactions and chemokine-receptor interac-
tions, we assessed the effects of three viral CMPs that target
chemokine binding to either the receptor binding domain (M-T1),
the GAG binding domain (M-T7), or both domains (M3). Cell
invasion and intimal plaque growth were measured in the mouse
aortic transplant model at 4 weeks follow up after treatment with
each CMP (Fig. 2, Table 1, n= 239, including controls). To
confirm the therapeutic targets for each CMP, effects were
assessed after WT donor aortic transplant (Ccr2+/+ and Ndst1+/+)
or after transplant of Ccr22/2 (Table 1, n= 165) or Ndst12/2
(n = 74) deficient donor aorta.
Treatment with myxomaviral M-T1 infusion at a dose of
600 ng significantly reduced both intimal plaque thickness to
medial thickness ratios and plaque area in WT Ccr2+/+ to C57Bl/6
recipient aortic allograft transplants (Table 1, n= 26, p,0.006,
Fig. 2A, E), but M-T1 did not decrease plaque growth in Ccr22/2
donor aortic allograft transplants (Table 1, n= 22, Fig. 2 B, E,
p = 0.610). Infusion of M3 at similar doses reduced plaque in WT
Ccr2+/+ Balb/c donor to WT C57Bl/6 aortic transplants (n = 25,
p,0.005, Fig. 2F), but not in Ccr22/2 donor transplants (Table 1,
n = 22, p = 0.55, Fig. 2F), showing a trend toward increased
plaque area. Analysis of variance (ANOVA) for M-T1 and M-T7
was significant (p,0.005 and p,0.008, respectively).
Mean plaque area paralleled the changes detected on analysis of
intimal/medial thickness ratios. Specifically M-T1 and M3
Donor Recipient Treatment Dose Total number Number 4 weeks
NDST-1+/+ (C57Bl/6) WT (C57Bl/6) M-T7 6 mg 6 6
Subtotal 13 12 (92%)
Total 239 221 (92%)
doi:10.1371/journal.pone.0010510.t001
Table 1. Cont.
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reduced plaque area in Ccr2+/+ donor aortic allografts (plaque
area = 0.156.037 mm2 for saline, plaque area = 0.0378
6.012 mm2 6 for M-T1 600 ng and 0.0266.004 mm2 for M3
600 ng; p,0.013 for M-T1 600 ng dose and p,0.031 for M3
600 ng dose), with no significant reduction of plaque area in
Ccr22/2 donor allografts (plaque area = 0.069 mm2 for saline,
0.0686.03 mm2 for M-T1 600 ng, and 0.1796.073 mm2 for M3
600 ng, p= 0.36). M-T7 also reduced intimal/medial thickness
ratios and plaque area after transplant of WT Balb/c donor
(Ccr2+/+) to C57Bl/6 (Fig. 2, C; p,0.003 for 600 ng and 6 mg
doses) (Table 1, n= 35, Fig. 2C, G; ANOVA, p,0.0003).
Conversely, although plaque size was already reduced in the
Ccr22/2 Balb/c donor allograft model, M-T7 significantly
reduced intimal plaque thickness at the higher doses of 0.6 mg
Figure 1. Local, but not systemic, GAG or receptor deficiency reduces neointimal hyperplasia in mouse aortic allograft transplants.
Histology cross sections of aortic allograft transplants stained with Masson’s trichrome demonstrating reduced inflammatory cell invasion with Ndst1-
deficient (Ndst12/2) (B) and Ccr2-deficient (Ccr22/2) (D) donor aortic allografts when compared to wild type (WT)(A, B). Bar graphs demonstrate
similar, significant reductions in mean neointimal area for Ccr22/2 (D) and Ndst12/2 (E) transplants. Reduced intimal area is detected with donor aortic
deficiency, but not with recipient deficiency (F, reverse transplant WT into Ccr22/2 or Ndst12/2 deficient recipient mice). Measurements reported as
mean 6 S.E. Arrows bracket intimal plaque, arrow heads indicates mononuclear cell infiltrates. Mag 400X.
doi:10.1371/journal.pone.0010510.g001
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and 6 mg (Fisher’s PLSD p,0.050, ANOVA p,0.0003) (Table 1,
n = 41, Fig. 2 D, G).
Changes in mean plaque area in WT (Ccr2+/+) donor allografts
again paralleled changes detected by analysis of intimal to medial
thickness ratio. M-T7 reduced mean plaque area at both 600 ng
and 6 mg dosing in aortic allografts (mean plaque area
0.156.037 mm2 for saline, 0.0456.022 mm2 for M-T7 600 ng,
0.037 mm26.017 for M-T7 6 mg) (ANOVA, p,0.021; p,0.027
for M-T7 600 ng dose, p,0.013 for 6 mg dose). M-T7 also
significantly reduced plaque growth in Ccr22/2 aortic allografts
(mean plaque area 0.0696.019 mm2 for saline, 0.0366.010 mm2
for M-T7 600 ng, 0.0206.007 mm2 for M-T7 6 mg, p,0.024 for
600 ng dose and p,0.003 for 6 mg dose). The maximum doses of
M-T1 and M3 used for these studies at 600 ng had no
demonstrated trend toward reducing plaque in the Ccr22/2 donor
allograft mouse aortic transplant models (Fig. 2 E, F).
M-T7 treatment significantly reduced intimal/medial thickness
ratios and plaque area in WT (Ccr2+/+) recipient reverse
transplants (p,0.030), but only produced a non-significant trend
toward reduced plaque in the WT C57Bl/6 to Ccr22/2 reverse
transplants (Fig. 2H, p= 0.442, ANOVA p=0.326, Table 1,
n = 26). M-T7 reduced plaqu‘e in the Ccr22/2 isografts, but this
reduction did not reach significance, although there is a trend
toward a reduction in plaque size (mean plaque area for saline
treated Ccr22/2 0.05760.045 mm2 and for M-T7 treatment
0.01360.006, p= 0.602).
In summary, M-T1 and M3, viral CMPs known to target
chemokine-receptor interactions, inhibited plaque growth in WT
Figure 2. Viral chemokine modulating proteins (CMPs) significantly reduce allograft neointimal hyperplasia with donor receptor
and GAG dependent specificity. H & E stained cross sections. M-T1 (A) and M-T7 (C) at 0.6 mg, or greater, doses reduced plaque in Ccr2+/+ aortic
transplants. M-T1 (B) did not inhibit intimal hyperplasia in Ccr22/2 donor allografts (B) whereas M-T7 did (D). Bar graphs illustrate significant
reductions in intimal to medial thickness with M-T1 (E), M3 (F), and M-T7 treatment of Ccr2+/+ donor allografts, whereas M-T1 (E) and M3 (F) are
inactive in Ccr22/2 donors. M-T7 did significantly reduce intimal hyperplasia in Ccr22/2 donor allografts (G). Reverse transplant to WT Ccr2+/+ mice did
significantly reduce intimal area, but Ccr22/2 recipients show only a trend toward reduction with M-T7 treatment (H). Measurements reported as
mean 6 S.E. Arrows bracket intimal plaque. Arrowheads point to inflammatory cell invasion. Mag. 200X.
doi:10.1371/journal.pone.0010510.g002
Chemokine-GAG in Transplant
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aortic transplant models, but displayed reduced activity in Ccr22/2
donor to WT C57Bl/6 recipient mouse aortic transplants. M-T7,
a CMP postulated to target chemokine-GAG interactions, reduced
plaque growth in WT aortic transplant models, and significantly
reduced plaque growth in the Ccr22/2 donor allografts, even
compared to the already reduced plaque growth seen in the
Ccr22/2 allograft mice.
M-T7 inhibition of plaque growth is blocked in Ndst-1
deficient mouse aortic transplants
The preceding studies indicated that M-T7 retained inhibitory,
anti-inflammatory activity in Ccr22/2 aortic allograft transplants,
indicating that M-T7 anti-inflammatory activity is not dependent
upon Ccr2. To test whether M-T7 inhibitory action is mediated
through blockade of chemokine to heparan sulfate GAG binding,
we examined WT (C57Bl/6 background, Ndst1+/+) donor to WT
Balb/c recipient aortic allograft transplants and Ndst12/2 donor to
WT Balb/c recipient mouse aortic allograft transplants, with and
without treatment with M-T7 (Table 1, n = 74). M-T7 significantly
reduced intimal/medial thickness in the WT C57Bl/6 (Table 1,
n = 12, p,0.032)(Fig. 3A) transplants, but did not further reduce
plaque in the Ndst12/2 mouse donor allografts (Table 1, n= 12,
Fig. 3A, p= 0.933, ANOVA p=0.072).
As for the prior studies, changes in mean intimal plaque area
with M-T7 treatment closely paralleled changes in intimal
thickness. Mean plaque area was significantly reduced with M-
T7 treatment in WT C57Bl/6 aortic donor allografts (mean
plaque area = 0.0956.032 mm2 for saline, 0.0346.014 mm2 for
M-T7 600 ng, p,0.012), but not in Ndst12/2 donor allografts
(mean plaque area = 0.0366.024 mm2 for saline,
0.0166.009 mm2 for M-T7 600 ng, p = 0.306), although a trend
toward a reduction is detected with M-T7 treatment. M-T7
treatment of WT C57Bl/6 donor to Ndst12/2 recipients (reverse
transplants), again demonstrated a loss of M-T7 inhibitory activity
(Fig. 3B, p = 0.588), whereas in the C57Bl/6 recipients M-T7
retained inhibitory activity (Fig. 3B, p,0.050).
M-T1 treatment was also tested in Ndst12/2 aortic allografts
(Table 1, n= 11). While not significantM-T1 treatment did produce
a trend toward reduced intimal/medial thickness (p= 0.222) and
area (p= 0.245) in Ndst12/2 aortic allografts (Fig. 3C).
Figure 3. M-T7 CMP loses inhibitory activity in Ndst12/2 donor allografts. Bar graphs of intimal/medial thickness ratios measured in aortic
transplant cross-sections at 4 weeks follow up post transplant. M-T7 reduced plaque in WT (C57Bl/6, Ndst1+/+) donor (P,0.032), but not in Ndst12/2
donor (P = 0.933) to Balb/c recipient allografts (A). In the reverse transplant of Balb/c to WT (C57Bl/6, Ndst1+/+) M-T7 again reduced plaque (P,0.050),
but not in Balb/c to Ndst12/2 transplants (P = 0.588). M-T1 treatment reduced plaque in Ndst12/2 donor aortic transplanted mice at 4 weeks follow
up (C), but this trend is non significant (P = 0.222). Measurements reported as mean 6 S.E.
doi:10.1371/journal.pone.0010510.g003
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These studies suggest that the mode of action of M-T7 depends
on fully sulfated heparan sulfate in the endothelial layer of the
transplanted arteries in order to block vascular inflammation and
plaque growth, consistent with M-T7 binding to the GAG binding
domain C-termini of chemokines. M-T7 also did not reduce
plaque significantly in the WT Balb/c to Ndst12/2 transplant
model (Fig. 3B)(P = 0.548) suggesting both local and systemic
effects of Ndst1 deficiency on M-T7 activity. M-T1 also had
reduced inhibitory activity in Ndst1 deficient donor allografts,
M-T7 prolongs survival and reduces inflammatory cell
invasion in renal allograft transplants
While the aortic allograft model provides a selective analysis of
vascular changes after transplant, the vasculature in whole organ
allograft transplant may or may not respond in a similar manner.
Thus, renal allograft transplants were performed without im-
munosuppression and either saline treatment or M-T7 treatment
for 10 days post transplant (n = 12). Transplant of one C57Bl/6
donor kidney into Balb/c mice with recipient mouse kidneys
removed at time of transplant, causes early mortality with a
median survival of 22.768.1 days after treatment (Fig. 4A). M-T7
treatment significantly prolonged survival to 100 days (Fig. 4A,
p,0.001), the experimental endpoint for histological analysis.
Immunohistochemical staining at 100 days demonstrated reduced
CD4 (p,0.0001) and CD8 (p,0.002) positive T cells as well as
macrophage (Mac-1, P,0.0001) invasion with M-T7 treatment
(Fig. 4B, ANOVA p,0.001), despite the fact that there was no
additional immunosuppressive therapy.
Effect of deficiency or blockade of chemokine-GAG and
chemokine-receptor interactions on inflammatory cell
migration in aortic transplant models
Comparisons of invasion of inflammatory mononuclear cells in
Ccr22/2 donor allograft (to C57Bl/6 recipient) (Fig. 5) and in
Ndst12/2 donor (to Ndst1+/+ Balb/c recipient) (Fig. 6) with WT
aortic allograft transplants was assessed by immunohistochemical
cell staining of aortic cross sections. Cell invasion was reduced at 4
weeks follow up for both Ccr22/2 (Fig. 5) and Ndst12/2 (Fig. 6)
aortic donor allografts with saline control treatment, when
compared to WT donor controls (Ccr2+/+and Ndst1+/+, respec-
tively). Selective staining for CD3-positive T cells (CD3+)
demonstrated significant reductions in CD3+ T cells in saline
treated Ccr22/2 donor aortic allografts (Fig. 5C, E; p,0.0001)
when compared to Ccr2+/+ controls (Fig. 5A, E). Compared to
controls, macrophage counts were not significantly reduced in
Ccr22/2 aortic allografts (Fig. 5F, p = 0.106).
Both CD3+ T cells (P,0.009) and macrophage (p,0.0001)
counts in the adventitial arterial layers were reduced in Ndst12/2
donor aortic allografts (Fig. 6A–D) (ANOVA for macrophage -
p,0.007 intima and p,0.0001 adventitia; ANOVA for CD3
positive T cells - p = 0.162 intima and p,0.l034 adventitia) when
compared to WT Balb/c controls. Greater reductions in cell
invasion in the adventitial layers (Figs. 5 and 6) were detected for
both CD3+ T cells and macrophage in Ccr22/2 and Ndst12/2
donor aortic transplants than in intimal layers.
Treatment with the viral CMPs M-T1, M-T7, or M3 also
significantly reduced T cell and macrophage invasion in WT C57Bl/
6 donor transplants in mice (ANOVA p,0.0001 for T cell invasion
and p,0.0129 for macrophage) at 4 weeks follow up (Fig. 5A,B, E, F).
The inhibitory activity of all three CMPs was lost in Ccr22/2 mouse
aortic donor transplant when comparing similar 600 pg and 600 ng
doses for all three CMPs (Fig. 5E, F), however, M-T7 significantly
reduced CD3+ T cell counts in the adventitia at the higher 6 mg dose
(Fig. 5D, p,0.05; data not shown as comparable high dose M-T1
and M3 not available). A non-significant trend toward inhibition of
macrophage invasion by the three CMPs was also observed in
Ccr22/2 donors after treatment with the three proteins.
M-T7 was capable of inhibiting macrophage invasion into the
intima (Fig. 6A, P,0.003) and adventitia (Fig. 6B, p,0.001) and
CD3+ T cells (Fig. 6C, p,0.021) into the adventitia of WT
C57Bl/6 mouse donor aorta transplants. In contrast, M-T7
inhibition of cell invasion was no longer evident in Ndst12/2 donor
aortic allografts (Fig. 6A–D, p=NS).
These findings indicate a persistent reduction in inflammatory
cell invasion at 4 weeks follow up in donor allografts with Ccr2 or
Ndst1 genetic deficiency or after treatment of WT donor allografts
with the CMPs. CMP inhibitory activity for cell invasion was
reduced in Ndst12/2 and Ccr22/2 donor allografts to varying
degrees, dependent upon the individual CMP tested.
Figure 4. M-T7 CMP treatment of mouse renal allograft transplant recipients markedly prolongs survival. A. M-T7 treatment alone,
with no added immunosuppressive treatment, markedly improved survival of mice to 100 days follow up after renal allograft transplant (100%
survival) when compared to controls given no treatment (median survival 22.768.1days, 0% survival past 30 days, P,0.001). B.M-T7 also significantly
reduced macrophage (Mac-1)(P,0.0001) and CD4 (P,0.0001), CD8 (P,0.002) positive T cell invasion as assessed by analysis histology score on
immunostained cross sections taken at follow up. Measurements reported as mean 6 S.E.
doi:10.1371/journal.pone.0010510.g004
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Early inflammatory cell migration in response to
chemokine injection in mouse ascites is reduced with
Ndst1 or Ccr2 deficiency or CMP treatment
A mouse peritoneal ascites model provides a direct assessment
of chemokine taxis gradient induced cell migration in the presence
or absence of GAG (Ndst1) or chemokine receptor (Ccr2)
expression or after CMP treatments. Observed late reductions in
plaque inflammatory cell invasion and growth are predicted to be
the result of early changes in inflammatory cell responses to
chemokine interactions with tissue GAGs and cell receptors. Thus,
early and selective chemokine-induced changes in cell migration
into the peritoneum of mice were assessed after i.p. chemokine
injection. Injection of each of the CC chemokines, MCP-1,
RANTES, and MIP1a, increased mononuclear cell migration into
the peritoneal cavity. MCP-1 and RANTES produced the most
consistent changes in the mouse models and the results of injection
of MCP-1 and RANTES are reported here (MCP-1 shown in
Fig. 7A, B, D; RANTES shown in Fig. 7C).
Reductions in migrating cell numbers after i.p. CC chemokine
injection in both Ccr22/2 (Fig. 7A, B, p =NS) and Ndst12/2
(Fig. 7D, p,0.05) mice were detected after saline control
treatment in comparison to WT Balb/c or C57Bl/6 controls,
respectively (Ccr2+/+, Fig. 7A, or WT Ndst1+/+, Fig. 7D). M-T1
Figure 5. Interference with chemokine-CCR2 interactions reduces inflammatory cell invasion in aortic allografts. Immunohistochem-
ical staining of aortic allograft transplant cross sections demonstrated increased lymphocyte (A) invasion in WT (Balb/c, Ccr2+/+) donor aortic
transplants at 4 weeks. M-T7 reduced T cell invasion in the WT Balb/c donor transplants (B). In the Ccr22/2 transplants T cell invasion was reduced at 4
weeks in saline treated mice (C), without further significant reduction with M-T7 treatment (D). Bar graphs demonstrate reduced T cell invasion
(P,0.0001), but not macrophage (P = 0.106) in Ccr22/2 saline treated allografts when compared to saline treated Ccr2+/+ allografts. M-T1, M-T7, and
M3 treatment significantly reduced T cell (P,0.001)(E) and macrophage (P,0.029) (F) invasion in the WT (Balb/c, Ccr2+/+) donor aortic allograft
transplants, but not in Ccr22/2 donor allografts (P =NS)(E,F). Measurements reported as mean 6 S.E. Arrow heads point to brown, positively stained
CD3+ T cells. Arrow points to blue stained suture seen in the top left corner of panel D. Mag 1000X.
doi:10.1371/journal.pone.0010510.g005
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reduced cell invasion in WT Balb/c (Fig. 7A, p,0.041), but
produced a non-significant increase in cell invasion in Ccr22/2
mice (Fig. 7B, P= 0.069). M-T7 reduced cell invasion in both WT
Balb/c (Fig. 7A, P,0.041) and in Ccr22/2 (Fig. 7B, P,0.009)
mouse models. The capacity of M-T7 to block early chemokine
mediated cell invasion was further assessed after injection via
systemic (i.v.) or local (i.p.) routes (Fig. 7C). M-T7 was equally
active when given by i.v. or i.p. injections indicating a local
inhibitory action (Fig. 7C, p,0.0007). Conversely, M-T7 reduced
cell invasion in Ndst1+/+ (Fig. 7D, p,0.019), but not in Ndst12/2
mouse models (Fig. 7D, p= 0.331).
This study indicates that either Ccr2 or Ndst1 deficiency produced a
non-significant reduction in early cell invasion in response to CC
chemokine peritoneal injection. The CMPs, M-T1 and M-T7, both
inhibit cell migration in response to local i.p. CC chemokine
injections inWTBalb/c mice. Further, this inhibition is lost in Ccr22/
2mice forM-T1 treatment, but not for M-T7 treatment. Conversely,
M-T7 inhibitory activity is lost in Ndst12/2 mice, although a trend
toward a reduction is still detectable. M-T7 was equally active in WT
mice whether given as a systemic (i.v.) or local (i.p.) injection.
Discussion
With these studies we have detected equivalent blockade of
allograft plaque growth after local interruption of either chemo-
kine-GAG or chemokine-receptor interactions, whether produced
by genetic deficiency or chemokine modulating protein (CMP)
treatment. M-T7 treatment also markedly prolonged renal
allograft survival in a mouse renal transplant model. The
chemokine-GAG interaction has thus proven to be a central
regulatory step in the inflammatory responses in mouse aortic and
renal allograft models. We have also unexpectedly detected a
predominant local effect inherent to donor aortic allografts that
manifests when chemokine interactions with either GAG or Ccr2
receptor are blocked. Although chemokines are predicted to have
a local effect on inflammatory responses, circulating inflammatory
cells (T cells and monocytes) are believed to respond to
chemokines through their receptors [5–9]. Chemokines and
receptor interactions can also modify cellular movement into
and out of the bone marrow and secondary lymphoid organs,
suggesting that a systemic deficiency would also alter inflammatory
cell responses post-transplant [5–9]. We have found a marked
local effect of GAG or receptor deficiency in donor allografts, but
not with deficiency in allograft recipients, suggesting a focal effect
transmitted with transplant of the donor organ. These studies
indicate that targeting the chemokine-GAG interaction represents
a promising target for new therapeutic approaches.
Further, the CMPs targeting chemokine binding to receptor or
GAG were active when given as a systemic (i.v.) dose, but these
proteins were only able to block intimal hyperplasia when the
Figure 6. Interference with chemokine-GAG interactions blocks inflammatory cell invasion in aortic allografts. Bar graphs illustrate
mean cell count per high power field (HPF) in cross sections taken from WT (C57Bl/6, Ndst1+/+) and Ndst12/2 donor aortic allografts at 4 weeks follow
up. Macrophage counts are reduced with M-T7 treatment in Ndst1+/+ donor sections in the intimal (A, P,0.003) and adventitial layers (B, P,0.0001).
CD3+ T cell counts are also reduced at 4 weeks follow up with M-T7 treatment in WT (C57Bl/6, Ndst1+/+) donor allografts in both intimal (C) and
adventitial (D) layers, but only adventitial counts were significantly altered (P,0021). M-T7 treatment did not reduce either macrophage or CD3+ T
cell counts in Ndst12/2 donor aortic allografts (A,B,C,D). Measurements reported as mean 6 S.E.
doi:10.1371/journal.pone.0010510.g006
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donor aorta expressed the appropriate chemokine binding target.
In these studies local (donor) transplant deficiency of Ccr2 and HS
GAG significantly blocked inflammatory cell invasion and
allograft plaque growth but systemic deficiency had no effect.
Disruption of local GAG expression is expected to interrupt
chemokine gradient formation and directionality of inflammatory
cell migration. However, CCR2 is generally thought to be
expressed on inflammatory cells and mediates responses to tissue
chemokine gradients bound to GAGs. Thus, the finding of a
reduction in allograft inflammation and plaque in Ndst1 deficient
mouse donors is expected, but the same reduction in Ccr2 deficient
mice was unexpected. One can postulate that either reactive
‘passenger’ inflammatory leukocytes are implanted at the time of
surgery, that other cells in the donor allograft are responding, or
that the activation of cells in response to CCR2 activation in the
donor allograft has more extensive effects than are generally
understood. Certainly others have indicated that chemokines and
their receptors have much broader effects on cellular responses
and that our understanding of chemokine function is as yet
incomplete [9].
Prior studies in Ccr2 deficient mice have demonstrated variable
effects, with minimal effect when transplanting hearts [27] or
thoracic aorta [42] into Ccr22/2 mice, but a significant reduction
in rejection for pancreatic islet cell transplants [27]. Although
GAG deficiency on the donor endothelium is expected to alter
inflammatory responses, chemokine receptor deficiency is more
difficult to understand. Based upon the findings in this study, we
postulate that other cells, outside of the circulating blood, and
within the arterial wall such as intimal endothelium, medial
smooth muscle cells, and adventitial macrophage or fibroblasts
have the potential to express chemokine receptors and to respond
to chemokine stimulation. Thus deficiency of CCR2 in the donor
aorta can alter migration of endothelial cells, smooth muscle cells,
or adventitial cells in the allograft. One prior study has detected no
difference in intimal hyperplasia after either donor or recipient
thoracic aortic allograft transplant into the abdominal aorta in a
mouse model at 8 weeks post transplant. The differences in the
results of our study for donor Ccr22/2 allografts may be the result
of an earlier follow up at 4 weeks, the use of a thoracic aortic
segment for transplantation, or the use of Balb/c Ccr22/2 strain
versus a C57Bl/6 background, when compared to this prior aortic
transplant study [42]. Certainly other groups have recently
reported a reduction in intimal plaque after local [43] or systemic
blockade of Ccr2 in vein graft transplants [44].
Figure 7. CMP treatment reduces early and local cell invasion into mouse peritoneal ascites in response to chemokine injections.
FACS analysis of cell invasion counts at 18 hours into mouse peritoneal fluid in response to either MCP-1 i.p. injection (A,B,D) or RANTES i.p. injection
(C). MCP-1 and RANTES both significantly increased cell migration into the peritoneal space (ascites) in WT mice (A, C, D). M-T1 and M- T7 both
reduced cell invasion in WT (Balb/c, Ccr2+/+) mice (A), but M-T7 alone was able to reduce cell invasion in Ccr22/2 mice (B). M-T7 also reduced cell
migration into ascites in WT (C57Bl/6, Ndst1+/+) mice (P,0.019, D) but not into Ndst12/2 mice (P = 0.331, D). M-T7 given either locally into the
peritoneal space (I.P.) or systemically by I.V. tail vein injection was equally effective at reducing cell migration in WT mice (C). Measurements reported
as mean 6 S.E.
doi:10.1371/journal.pone.0010510.g007
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Conditional genetic deficiency in heparan sulfate GAG (Ndst12/2)
and genetic deficiency in the CC receptor 2 (Ccr22/2) produced
comparable reductions in vascular inflammation and plaque
growth. While the studies with Ndst1 and Ccr2 deficient models
demonstrated potentially equivalent roles in donor allografts, this
does not constitute direct proof of selective interruption of
chemokine-mediated interaction with HS GAG. Therefore we
tested the effect of using CMPs derived from viruses to block
either the chemokine-receptor or chemokine-GAG interactions.
The targets for each CMP were further defined by comparing
activity in both the WT Ndst1+/+ and WT Ccr2+/+ allografts and in
the deficient Ndst12/2 and Ccr22/2 donor aortic allografts. With
CMP treatment there was again a comparable reduction in
inflammatory cell invasion and plaque growth. As predicted, M-
T1 and M3 lost activity in Ccr22/2 mouse models, whereas M-T7
retained inhibitory activity. Conversely, M-T7 lost inhibitory
activity in the Ndst12/2 mouse model. M-T1, however, while
displaying a trend toward a reduction in both measurements of
plaque area and intimal/medial thickness ratios, this reduction
was not significant, suggesting that HS-GAG deficiency has wider
ranging effects on chemokine interactions. Similarly, while M-T1
and M3 lost inhibitory activity for macrophage and CD3+ T cell
invasion in Ccr22/2 aortic allografts, M-T7 also lost activity at
comparable doses. Thus more extensive analysis of cellular
responses is required to precisely determine the inflammatory cell
targets for individual CMPs.
In order to define whether these cell invasion responses were the
result of a directed effect against chemokine interactions, we
examined chemokine mediated inflammatory cell invasion using a
mouse peritoneal ascites cell migration model. In this model a
chemokine gradient is induced by local injection of selected CC
chemokines into the peritoneal space and early cell migration in
response to chemokine injection with or without CMP treatment is
then assessed. These assays allowed an analysis of early and
selective CC chemokine mediated cellular responses. Inhibition of
cell migration in response to the CMP treatments was again
selectively lost for M-T1 in CCR2 deficient mice (Fig. 7A,B) and
for M-T7 in HS-GAG deficient (Fig. 7D) mice, indicating that
these inhibitory proteins do alter early cellular migration and
invasion in response to chemokine activation. Further, immunos-
taining for CD3 positive T cells and macrophage at 4 weeks
differentiated Ccr2 and Ndst1 deficiency, with Ccr22/2 having
more effect on T cell and Ndst12/2 on macrophage invasion in the
adventitial layer, further suggesting the adventitia has a role in
inflammatory vascular responses. Thus although a direct chemo-
kine-receptor or chemokine-GAG interaction may not be demon-
strated in the transplant models, this cell migration model does
provide a direct analysis of chemokine induced cell migration.
These findings therefore suggest that the loss of inflammatory
responses and transplant plaque growth with M-T7 treatment is
indicative of interference with chemokine-GAG interactions.
Chronic transplant rejection is generally considered to be the
result of both recurrent episodes of acute rejection as well as chronic
inflammation mediated damage [9–23,26–28]. Chronic transplant
scarring is often associated with vascular inflammation and
occlusion at sites of scar formation and is believed due to both
local and systemic or circulating cellular responses [10–15]. Thus
circulating or systemic levels of chemokine receptors or GAGs have
the potential to alter transplant rejection responses in addition to
donor allograft based chemokines. Other researchers have sug-
gested that vascular transplant alone is more representative of
surgical trauma than of a true organ and/or vascular rejection
response [45]. To determine whether the findings with the aortic
transplant model studies are specific only to local transplanted
allograft vessels or to this model alone, a mouse renal allograft
model was also examined. M-T7 alone (no standard immunosup-
pressant treatment), reduced rejection and significantly prolonged
survival. Thus, rather than simply confirming a reduction in
vasculopathy and scarring, a highly significant prolongation of
survival was detected. Co-treatment of M-T7 with cyclosporine has
been previously reported to reduce inflammation and scarring in
renal allograft transplants in a rat model [40]. However, M-T7 was
not tested independent of adjuvant cyclosporine treatment in the rat
renal transplant model. This current finding would suggest that M-
T7, and potentially interference with chemokine-GAG interaction,
provides a highly effective mechanism for blocking transplant
rejection and may alter both acute and chronic rejection response.
Thus one can either predict a potential separate additional activity
for M-T7 or one can postulate that interference with the
chemokine-GAG interaction is sufficient to block lymphocyte as
well as monocyte mediated acute and chronic rejection responses.
Genetic deficiency for GAG or Ccr2 has, however, not been
assessed in this mouse renal transplant model and further
examination of chemokine-GAG and chemokine-receptor interac-
tion in this model is anticipated. Thus one can either predict a
potential separate additional activity for M-T7 or one can postulate
that interference with the chemokine-GAG interaction is sufficient
to block lymphocyte as well as monocyte mediated acute and
chronic rejection responses. Given the profound local effects of
GAG deficiency on allograft inflammation and neointimal hyper-
plasia, we would postulate that M-T7 treatment and blockade of
local chemokine binding to GAGs and inhibition of cell taxus is
sufficient to explain the reduced inflammation and prolongation of
allograft survival. Further studies will be necessary to precisely
identify the mechanism of action of M-T7.
In summary, interference with chemokine-GAG interactions in
donor aortic allograft transplants significantly inhibits accelerated
transplant plaque growth, a reduction equipotent to blockade of
chemokine-CCR2 interactions. These findings suggest that inter-
ference with inherent chemokine responses in donor allograft
tissue has greater therapeutic effect. Treatment with the viral
chemokine modulating protein M-T7 significantly reduced
accelerated aortic allograft plaque growth. Of even greater interest
M-T7 treatment given alone, with no additional immunosuppres-
sant treatment, also markedly improved survival of mouse renal
allografts. Interference with local chemokine-HS GAG interaction
represents a promising new therapeutic target for vascular
inflammatory disorders and transplant vascular rejection.
Methods
Surgical procedures
All animal surgical research protocols were performed in strict
accordance with good animal practice, were approved by local
laboratory animal care committees at the University of Western
Ontario (London, Canada) and University of Florida (IACUC,
Gainesville, USA), and conformed to the Guiding Principles for
Animal Experimentation; Protocol numbers E907 and F111.Pro-
tein or control saline treatments (0.1 ml/mice) were given by
intravenous (i.v.) injection (tail vein) immediately after aortic
allograft transplant or immediately after renal transplant and for 9
subsequent daily tail vein i.v. injections. No increase in mortality
was detected for aortic transplant models, chemokine injection for
cell migration assays, mouse knock out models, or with CBP
treatments. Survival rates for aortic transplant surgeries ranged
from 86 to 100%. For the mouse renal transplant model, untreated
animals survived 22.768.1 days while treated animals survived to
the 100 day follow up time point.
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Ccr2 deficient (Ccr22/2) mice (Balb/c background) were kindly
provided by Dr. I. Charo [Whitehead Institute, San Francisco,
CA.) [15]. The Ndst12/2 mouse strain (Ndst1f/fTek/Cre+, C57Bl/6
background) and appropriate control Ndst1+/+ mice (Ndst1f/
fTekCre-) were provided by Dr. J. Esko (Glycobiology Research
and Training Center, University of California, San Diego, CA.)
[4]. Mice were bred by brother sister mating in the ACVS of
University of Western Ontario and at the University of Florida. All
mice were genotyped prior to use. Littermate controls were used
for all Ndst12/2 to Ndst1+/+ comparison analyses. Wild type
C57Bl/6 and Balb/c mice were obtained from JAXLabs (Bar
Harbor, MN, U.S.A.).
Aortic Allograft Transplants
In total, 239 mice had aortic allograft transplant surgery
(Table 1). For analysis of effects of Ccr2 deficiency, 60 Ccr2+/+
(Balb/c background) donor to WT C57Bl/6 recipient mice and 65
Ccr22/2 (Balb/c background) donor to WT C57Bl/6 recipient
mice underwent aortic transplant surgery. 14 Ccr22/2 Balb/c
mice also had isograft transplant and 26 mice had reverse WT
C57Bl/6 donor to Ccr2+/+ or Ccr22/2 recipient transplant. To
assess potential effects of Ndst1 conditional deficiency, 12 Ndst1+/+
donor (C57BL/6 background) to WT Balb/c and 12 Ndst12/2
(C57Bl/6 background) to WT Balb/c aortic allograft transplants
were performed. Reverse transplants, 9 Ndst1+/+ (Balb/c back-
ground) to Ndst1+/+ (C57Bl/6 background) and 12 Ndst1+/+ Balb/c
to Ndst12/2 (C57Bl/6 background) underwent aortic allograft
transplant surgery to assess effects of systemic HS GAG deficiency.
All mice used for surgical studies weighed 25–30 gm and were fed
normal chow for the duration of the experiments. Under general
anesthetic (6.5 mg/100 g body weight Somnotrol, MTC Pharma-
ceuticals, Cambridge, ON, Canada) given by intramuscular (i.m.)
injection, a 0.3 cm aortic segment was isolated from donor mice and
transplanted into the infra-renal aorta of recipient mice for aortic
allograft or isograft transplant studies, as previously described
[39,40]. The aortic transplant was inserted via end-to-end
anastomosis using Sharpoint 11/0 nylon sutures (Surgical Special-
ties Corporation, Reiding, MA, USA) [39,46]. Mice were followed
for 4 weeks after transplant. A single infusion of each of the
individual proteins M-T1, M-T7, and M3 (0, 600 pg, 600 ng, or
6 mg; 0.02, 20, 200 ng/gm body weight in 0.2 ml) was injected i.v.
via tail vein immediately after transplant surgery, once aortic
pulsation was again visible. Animals were sacrificed with 0.05 ml
euthanyl (Bimeda- MTC Animal Health Ltd., Cambridge, ON,
Canada) intramuscular (i.m.) injection. The aortic allografts develop
excessive chronic arterial wall inflammation and neointimal
hyperplasia with accelerated plaque growth by the end of 4 weeks.
Orthotopic Kidney Transplantation
C57BL/6 mouse kidneys were transplanted into the abdomens of
Balb/c recipients by anastomosis of the donor and recipient aortas
and the donor renal vein and recipient inferior vena cava using 11–0
nylon sutures. The donor ureter was sutured to the recipient bladder
using 10–0 sutures. Native kidneys were removed immediately after
grafting. Graft rejection leading to death was used as the study
endpoint while mice with long-term surviving grafts were
euthanized at post-operative day (POD) 100 [47].
Histological, Immunohistochemical, and Morphometric
Analysis
Harvested arterial sections were processed and stained with
hematoxylin and eosin (H & E) or Masson’s trichrome stains as
previously described [35,37,39,40]. Plaque area, was measured by
morphometric analysis using an Olympus CCD color video
camera attached to an Olympus microscope, and the ImagePro
application program calibrated to the microscope objective [39–
41,46]. The mean total cross-sectional intimal area or the mean
intimal thickness normalized to the medial thickness were
calculated for each arterial section. Allograft specimens isolated
from recipient mice were cut into three sections and two histology
cross sections stained per each of the three allograft section (6
sections per specimen).
For immunohistochemical staining of aortic allograft sections,
formalin fixed tissues were labeled using an ABC kit (Vector
Laboratories, Burlingame, USA) as per the manufacturer’s
protocol. Tissue sections were blocked and labeled for CD3+ cells
using 1:100 primary antibody (rabbit anti-mouse CD3, Abcam,
Cambridge, USA), 1:250 biotinylated secondary antibody (goat
anti-rabbit IgG, Abcam) and avidin biotin complex (Vector
Laboratories), as previously described [39–41,46]. For renal
allografts, CD4+ and CD8+ cells were detected using the
biotinylated antibodies YTS 191.1.2 (Cedarlane Laboratories,
Hornby, Ontario, Canada) and 53–6.7 (BD Biosciences, Franklin
Lakes, NJ), respectively. Intragraft monocyte/macrophage infil-
tration was detected with a biotinylated anti-Mac-1 mAb
(Cedarlane). Diaminobenzidine (Sigma-Aldrich, St.Louis, USA)
was used for detection and sections were counterstained with
hematoxylin. Positively stained cells were counted in three high
power fields (HPF) areas for the intimal, medial and adventitial
layers of each aortic allograft section analyzed (4–6 sections per
mouse allograft specimen).
Flow Cytometry of Inflammatory Cell Responses in
Mouse Ascites
WT Balb/c and WT C57Bl/6 mice had 50 ng injections of
either MCP-1, MIP-1a or RANTES (Cedar Lane, Hornby, ON,
Canada) injected intra-peritoneally (i.p.) for analysis of cellular
migration at 18 hours after treatment. Mice were injected with
either saline, M-T1 or M-T7 at (600 ng to 6 mg) given i.v. or i.p.,
immediately after i.p. chemokine injection. In similar studies
Ndst12/2 (C57Bl/6 background) and Ccr22/2 (Balb/c back-
ground) mice were tested after i.p. injection of chemokine with or
without M-T1 or M-T7 treatment. Three mice were tested per
treatment group for all mouse ascites cell migration studies.
Peritoneal exudates from mice were collected with PBS peritoneal
wash containing 2% FBS and treated with RBC lysis buffer
(Ammonium chloride 0.15 M, potassium bicarbonate 10 mM,
EDTA 0.1 mM, ph 7.4) 18 hours after i.p. chemokine injection.
RBC free cells were isolated and centrifuging at 500 g for 5 min.
Total cell migration count into the mouse ascites lavage was
measured using FACS analysis (FACS Calibur, Becton Dickinson
Canada Inc., Mississauga ON) as previously described [48].
Source and Purification of M-T1, M-T7, and M3
Viral CBPs were expressed and purified to .90% purity on
silver stained gels as previously described [39–41]. In brief, M-T7
was isolated from baby green monkey kidney (BGMK) cells
infected with vaccinia vector expressing M-T7. M-T1 from
vMyxlac-T1gpt infected BGMK cell cultures. Concentrated
supernatants were fractionated by Mono QHR5/5 anion
exchange chromatography followed by gel filtration chromato-
graphy using a HiLoad Superdex 200 column (AmershamPahr-
macia Biotech Inc.). M3 with a six histidine tag at the carboxy
terminal (M3-his) was expressed by recombinant baculovirus-
infected insect cells (TN5 B1– 4, ECAAC, Xenova, Cambrid-
ge,England). Protein was purified from infected cell supernatants
on Ni2-NTA resin (Qiagen). Eluted proteins were subjected to
Chemokine-GAG in Transplant
PLoS ONE | www.plosone.org 13 May 2010 | Volume 5 | Issue 5 | e10510
sodium dodecyl sulfate 12% polyacrylamide gel electrophoresis
and visualized by silver staining and immunoblotting and judged
greater than 90% pure.
Statistical analysis
Statistical analysis was performed using Statview V5.01 (North-
Carolina, USA). The mean plaque area, ratio of intimal to medial
thickness measurements, or cell counts in the intimal, medial and
adventitial layers was calculated from measurements made on the
three sections taken from each aortic allograft specimen isolated
from each mouse at follow up (2 histology sections per section,
three sections per aortic allograft; 6 sections analyzed per mouse
allograft). Mean values were used for subsequent statistical
analyses. Multiple group comparisons were made using analysis
of variance (ANOVA) with Fishers PLSD (Protected Least
Significant Difference) and additionally unpaired, two-tailed
Student’s T test for subgroup analysis. All bar measurements are
reported as mean 6 standard error (S.E.) P values less than or
equal to 0.05 were considered significant.
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